CIBC Private Wealth Group
CLDX icon

CIBC Private Wealth Group’s Celldex Therapeutics CLDX Stock Holding History

CIBC Private Wealth Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$13.6K Hold
500
– – ﹤0.01% 2311
2025
Q3 		$12.9K Hold
500
– – ﹤0.01% 2296
2025
Q2 		$10.2K Hold
500
– – ﹤0.01% 2251
2025
Q1 		$7.57K Hold
500
– – ﹤0.01% 2325
2024
Q4 		$13.3K Hold
500
– – ﹤0.01% 2181
2024
Q3 		$17K Hold
500
– – ﹤0.01% 2228
2024
Q2 		$18.2K Hold
500
– – ﹤0.01% 2071
2024
Q1 		$20.8K Buy
+500
New +$20.5K ﹤0.01% 2028

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CIBC Private Wealth Group's CLDX Position: Q4 2025 in Review

CIBC Private Wealth Group held its Celldex Therapeutics (CLDX) position steady in Q4 2025 at 500 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2311.

CIBC Private Wealth Group first reported a position in CLDX in Q1 2024 and has held it in 8 quarters since. The position peaked at $20.8K in Q1 2024. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • CIBC Private Wealth Group held 500 shares of Celldex Therapeutics worth $13.6K as of Q4 2025.
  • CIBC Private Wealth Group left its Celldex Therapeutics share count unchanged in Q4 2025.
  • Celldex Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2311 holding.
  • CIBC Private Wealth Group first reported a position in Celldex Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • CIBC Private Wealth Group's Celldex Therapeutics position peaked at $20.8K in Q1 2024.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.